These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 1579399)

  • 1. Acellular pertussis vaccination of 2-month-old infants in the United States.
    Pichichero ME; Francis AB; Blatter MM; Reisinger KS; Green JL; Marsocci SM; Disney FA
    Pediatrics; 1992 May; 89(5 Pt 1):882-7. PubMed ID: 1579399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of an acellular pertussis vaccine booster in 15- to 20-month-old children previously immunized with acellular or whole-cell pertussis vaccine as infants.
    Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA; Meschievitz C
    Pediatrics; 1993 Apr; 91(4):756-60. PubMed ID: 8464662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of a diphtheria and tetanus toxoids and bicomponent acellular pertussis vaccine with diphtheria and tetanus toxoids and whole-cell pertussis vaccine in infants.
    Pichichero ME; Francis AB; Marsocci SM; Green JL; Disney FA
    Am J Dis Child; 1993 Mar; 147(3):295-9. PubMed ID: 8438811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An open study evaluating the reactogenicity and immunogenicity of a DTP vaccine containing an acellular pertussis component in four to six year old children.
    Lewis K; Cherry JD; Baraff LJ; Robinson RG; Dudenhoeffer FE; Holroyd HJ; Baker LR; Farchione SL; Gurwith M; Vernon S
    Dev Biol Stand; 1985; 61():563-9. PubMed ID: 2872132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-response to a two-component acellular pertussis vaccine in infants and comparison with whole-cell vaccine.
    Auerbach BS; Lake AM; Wilson ME; Willingham FF; Shematek J; Moulton L; Deforest A; Halsey NA
    Biologicals; 1998 Jun; 26(2):145-53. PubMed ID: 9811522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM; Rhodes P; Connelly BL; Bi D; Hahn C; Patrick S; Glodé MP; Ehresmann KR;
    Pediatrics; 2005 Aug; 116(2):e285-94. PubMed ID: 16061582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the safety and immunogenicity of acellular (BIKEN) and whole-cell pertussis vaccines in 15- to 20-month-old children.
    Marcinak JF; Ward M; Frank AL; Boyer KM; Froeschle JE; Hosbach PH
    Am J Dis Child; 1993 Mar; 147(3):290-4. PubMed ID: 8438810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary immunization series for infants: comparison of two-component acellular and standard whole-cell pertussis vaccines combined with diphtheria-tetanus toxoids.
    Feldman S; Perry CS; Andrew M; Jones L; Moffitt JE; Lamb D; Meschievitz C
    South Med J; 1993 Mar; 86(3):269-75, 284. PubMed ID: 8451663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative trial of the reactogenicity and immunogenicity of Takeda acellular pertussis vaccine combined with tetanus and diphtheria toxoids. Outcome in 3- to 8-month-old infants, 9- to 23-month-old infants and children, and 24- to 30-month-old children.
    Kimura M; Kuno-Sakai H; Sato Y; Kamiya H; Nii R; Isomura S; Horiuchi K; Kato T; Deguchi M; Saikusa H
    Am J Dis Child; 1991 Jul; 145(7):734-41. PubMed ID: 2058603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary immunization with a triple diphtheria-tetanus-whole cell pertussis vaccine in Iranian infants: an analysis of antibody response.
    Zarei S; Jeddi-Tehrani M; Akhondi MM; Zeraati H; Pourheidari F; Ostadkarampour M; Tavangar B; Shokri F
    Iran J Allergy Asthma Immunol; 2009 Jun; 8(2):85-93. PubMed ID: 19671937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of diphtheria-tetanus-two component acellular pertussis vaccines in United States and Japanese infants at 2, 4, and 6 months of age.
    Rothstein EP; Kamiya H; Nii R; Matsuda T; Bernstein HH; Long SS; Hosbach PH; Meschievitz CK
    Pediatrics; 1996 Feb; 97(2):236-42. PubMed ID: 8584384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minor adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Schmitt-Grohé S; Stehr K; Cherry JD; Heininger U; Uberall MA; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():113-8. PubMed ID: 9272341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA; Stehr K; Cherry JD; Heininger U; Schmitt-Grohé S; Laussucq S; Eckhardt T
    Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Quadrivalent vaccine against diphtheria, tetanus, B. pertussis and hepatitis B: experience in Spain].
    González López A; Arístegui Fernández J; Díez-Delgado J; Dal-Ré Saavedra R
    An Esp Pediatr; 1998 Feb; 48(2):132-7. PubMed ID: 9577019
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and reactogenicity of acellular diphtheria/tetanus/pertussis vaccines given as a pre-school booster: effect of simultaneous administration of MMR.
    Miller E; Waight P; Laurichesse H; Andrews N; Thornton C; Sesardic D; Corbel M
    Vaccine; 2001 Jul; 19(28-29):3904-11. PubMed ID: 11427264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical reactions and immunogenicity of the BIKEN acellular diphtheria and tetanus toxoids and pertussis vaccine in 4- through 6-year-old US children.
    Bernstein HH; Rothstein EP; Pichichero ME; Francis AB; Kovel AJ; Disney FA; Green JL; Marsocci SM; Lynd AM; Wood GC
    Am J Dis Child; 1992 May; 146(5):556-9. PubMed ID: 1621656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA; King J; Law B; Mills E; Willems P
    Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
    Chan SH; Tan PT; Han HH; Bock HL
    Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diphtheria and tetanus toxoids and pertussis vaccine adsorbed (DTP): response to varying immunizing dosage and schedule.
    Barkin RM; Samuelson JS; Gotlin LP
    Dev Biol Stand; 1985; 61():297-307. PubMed ID: 2872117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection.
    Heininger U; Stehr K; Christenson P; Cherry JD
    Clin Infect Dis; 1999 Mar; 28(3):602-4. PubMed ID: 10194085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.